It's that time again. The Benzinga Events team is busy planning for the third Cannabis Capital Conference back in one of our favorite spots and the heart of
the cannabis industry—Toronto.
The cannabis industry is constantly developing, from market expansions and stock volatility to recent regulations and everything
in-between. Benzinga recruits only the best executives and thought leaders for our conference, and this event is no exception.
Ahead of the April 17-18 event, the Benzinga Events team will showcase our exciting topics and discussions.
The Discussion
Canada-based Tilray Inc (NASDAQ: TLRY)
in late 2018 announced a partnership
with Sandoz to provide marijuana-related products to the dozens of countries where medical cannabis is legal. The partnership
lends further credibility to the medical cannabis sector, which enjoys higher levels of support
compared to recreational usage.
The financial benefit to companies selling medical cannabis could be much larger than the recreational market. Khurram Malik, an
analyst with Jacob Capital Management and CEO of producer Biome Grow,
told Canada's National Post a medical focused company can win approval for a cannabis-derived medicine and charge $200 a gram
-- more than 25 times more than what is charged to recreational users.
The Speakers
An expert panel will discuss the pharmaceutical side of the cannabis market. Speakers include:
- Dr. Christine Allen, Dean of Pharmacy, University of Toronto & Advisor, Avicanna;
- David Elsley, President and CEO, Cardiol Therapeutics (OTC: CRTPF); and
- J. Smoke Wallin, CEO, Vertical
Companies.
Check out the full agenda here and watch our LP panel from the
Miami Cannabis Capital Conference here.
Related Links:
What You Need To Know Ahead Of The 2019 Cannabis Capital Conference In Toronto
A Cannabis Bubble? Tim Seymour Believes Market Has Been 'Grossly Understated'
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.